Proteonomix, Inc. (PROT) Announces Receipt of First Order for Purchase of Proteoderm's Stem Cell Derived Cosmeceutical

MOUNTAINSIDE, NJ, May 19 (MARKET WIRE) --
Proteonomix, Inc. (PINKSHEETS: PROT) announced today that its subsidiary,
Proteoderm, Inc., has received its first international order for its stem
cell derived cosmeceutical kits. China Biopharma, Inc. and Sinoquest
Investment Limited, both based in China, have ordered $1 million worth of
kits. The order was received pursuant to an exclusive marketing and
distribution agreement entered into with the two companies in January
2009.

Pursuant to the purchase order, once Proteonomix confirms its ability to
fill orders for five times the quantity of the first order, the purchasers
will establish a letter of credit in favor of Proteonomix at an
international bank with offices in the United States to be designated by
the purchasers. Proteoderm will then manufacture the kits in bulk for
shipment to an international cargo facility at a U.S. airport designated
by the purchasers.

Michael Cohen, President of Proteonomix and Proteoderm, said, "We could
not have asked for a clearer confirmation of the extent of the present and
future market for the Proteoderm cosmeceutical, as well as the value of
our agreement with China Biopharma and Sinoquest."

Peter Wang, President of China Biopharma and Sinoquest, said that he is
excited about this first order and that his companies have already begun
the process of preparing the packaging, advertising and marketing of the
kits. "We have complete confidence that Proteoderm will fill this order
on a timely basis, and that additional orders will soon follow. We have
tested the anti-aging properties of the Proteoderm kit and its quality and
performance is far superior to anything else we've seen. We are pleased to
play a major role by being the first to bring this fine product to
market."

The Proteoderm kit contains five carefully matched cosmeceutical
products, three of which contain Proteoderm's proprietary, patent-pending
natural matrix of bioactive proteins called Matrix NC-138(TM), for use in
anti-aging skin care. The products have been shown to enhance the
stimulation of collagen and glandular production, leading to a reduction
in lines and wrinkles.

Fulfillment of this order is expected in July 2009.

About Proteonomix, Inc.

Proteonomix, Inc. is a biotechnology company focused on developing
therapeutics based upon use of human cells and their derivatives. Its
research and development program has demonstrated results with more than
ten patent applications and multiple products ready to enter respective
markets. Proteonomix has facilities at a number of academic institutions.
Its subsidiary, Proteoderm, Inc. has developed a line of anti-aging
cosmetics. For more information, please visit www.proteonomix.com or
www.proteoderm.com and www.pinksheets.com.

"Safe Harbor Statement."

Under the Private Securities Litigation Reform Act of 1995, statements
herein relating to the Company's expectations are forward-looking
statements. These statements, which address the Company's financial or
business outlook, apply only as of the date the information was issued.
Anticipated financial results may not occur.

Contact:
Michael Cohen
President, Proteonomix, Inc.
Phone: (973) 544-6116
Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-